Crinetics Pharmaceuticals, Inc. (CRNX) is a leading clinical-stage pharmaceutical company engaged in the discovery, development, and commercialization of novel therapeutics for the treatment of rare endocrine diseases and endocrine-related tumors. The San Diego-based company was founded by a team of scientists with a proven track record of endocrine drug discovery and development.
What sets Crinetics Pharmaceuticals apart is their commitment to developing innovative therapies that restore hormonal balance within the endocrine system. Their primary targeted patient populations are those suffering from endocrine diseases and tumors that are not adequately addressed by currently available therapies.
Crinetics’ flagship product is paltusotine (formerly known as CRN00808), an investigational, oral, nonpeptide somatostatin agonist for the treatment of acromegaly, an uncommon disease characterized by enlarged body parts due to the overproduction of growth hormone by the pituitary gland. Paltusotine has been granted Orphan Drug Designation in both the US and Europe for this indication.
In addition to paltusotine, the company also has a series of products in its pipeline. This includes CRN04777, an oral, nonpeptide, small-molecule somatostatin receptor 5 (sst5) agonist for the treatment of congenital hyperinsulinism (CHI), a rare pediatric genetic disorder. CRN04894, an oral, nonpeptide ACTH antagonist for the treatment of Cushing's disease, and CRN04846, an oral, nonpeptide sst2 agonist for the treatment of neuroendocrine tumors.
Crinetics is driven by a passion for patients who battle with these diseases and the healthcare providers who treat them. This patient-centric mindset informs its strategic approach, propelling the company to continuously strive for breakthroughs in scientific research and medical innovation. Crinetics’ commitment to scientific rigor and its collaborative culture underpin its approach to drug discovery and development and have made it a well-respected entity in its industry.
Overall, Crinetics Pharmaceuticals is a notable trailblazer in the field of endocrinology. It stands committed to delivering safer, effective therapies for patients afflicted with rare and severe endocrine disorders. Their pursuit of novel and innovative therapeutics is changing the dialogue of endocrine treatment, offering hope for patients across the globe. Weathering the complexities of clinical trials and scientific breakthroughs, Crinetics remains steadfast in its goal of creating a healthier, sustainable future for endocrine patients everywhere.